Researchers engineered a synthetic long peptide vaccine that successfully triggers immune killer cells against cancers that have disabled their normal antigen-processing machinery.
100% of tested donors had target T cellsLRPAP1-specific CD8 T cells were found in all healthy donors and lung cancer patients tested, suggesting the immune system is already primed to respond — it just needs the right vaccine trigger.
What the researchers found
The researchers identified that LRPAP1 signal peptide-specific CD8 T cells were present in the blood of all tested healthy donors and patients with non-small cell lung adenocarcinoma, confirming the immune system's inherent capacity to target this antigen.
However, the natural peptide sequence was poorly presented by dendritic cells due to a weak-binding serine at the C-terminus. Replacing this serine with a valine dramatically improved HLA-A2 binding affinity and T cell stimulation. Critically, T cells primed with the valine-modified variant still recognized the natural serine version and responded to TAP-deficient cancer cells. A systematic screen of extended peptide variants identified a 24-mer N-terminally elongated synthetic long peptide as the optimal vaccine candidate, ready for clinical trial validation.
Why it matters
Cancer immune evasion is one of the biggest obstacles in immunotherapy. When tumors disable their TAP machinery, conventional T cell therapies lose their targets. This TEIPP vaccine approach flips the script — targeting antigens that only appear when cancers try to hide. Because these antigens are absent from healthy tissue, the vaccine could attack tumors with minimal risk of autoimmune side effects, potentially rescuing patients whose cancers have escaped standard immunotherapy.
How the study worked
The researchers developed synthetic long peptide variants from the LRPAP1 signal sequence and tested cross-presentation by monocyte-derived dendritic cells. They performed anchor residue substitution experiments, HLA-A2 binding assays, and tetramer staining to evaluate T cell specificity. A functional screen of N- and C-terminally extended peptide variants was conducted to identify the optimal vaccine format. T cells from healthy donors and non-small cell lung cancer patients were tested for reactivity against TAP-deficient tumor cells.
What this study cannot tell us
This is preclinical research conducted in laboratory settings using cells from a limited number of donors and patients. The vaccine has not yet been tested in clinical trials, so its safety and effectiveness in actual cancer patients remain unknown. The study focused on HLA-A2-positive individuals, which represents only a subset of the population. Long-term durability of the induced T cell responses was not assessed.
How to read the evidence
This is a preclinical laboratory study demonstrating proof-of-concept for a peptide vaccine design. While the immunological data are compelling, no clinical trial results exist yet. The evidence supports the biological rationale and vaccine design but cannot confirm therapeutic benefit in patients.
When this study was published
Published in 2022, this study represents a vaccine candidate described as ready for clinical trial validation. Subsequent clinical development may be underway or in planning stages.
The bigger picture
This work represents an innovative approach in the cancer immunotherapy field — targeting immune-escaped tumors through their own evasion mechanism. TEIPPs join the growing arsenal of peptide-based cancer vaccines alongside neoantigen vaccines and tumor-associated antigen approaches. The concept that immune evasion creates new vulnerabilities could reshape how researchers think about treating treatment-resistant cancers.
Questions still open
- Will the TEIPP peptide vaccine prove safe and effective when tested in cancer patients in clinical trials?
- Can similar vaccines be designed for other TEIPP antigens beyond the LRPAP1 signal sequence to broaden tumor coverage?
- How frequently do human cancers lose TAP function, and could this vaccine approach benefit a substantial patient population?
Common questions
What are TEIPP antigens and why are they important for cancer treatment?
Why did the researchers need to modify the natural peptide sequence?
Read the original research
Cross-presentation of a TAP-independent signal peptide induces CD8 T immunity to escaped cancers but necessitates anchor replacement.
Cancer immunology, immunotherapy : CII, 71(2), 289-300
Citation
Marijt, Koen A; Griffioen, Lisa; Blijleven, Laura; van der Burg, Sjoerd H; van Hall, Thorbald. (2022). Cross-presentation of a TAP-independent signal peptide induces CD8 T immunity to escaped cancers but necessitates anchor replacement.. Cancer immunology, immunotherapy : CII, 71(2), 289-300. https://doi.org/10.1007/s00262-021-02984-7